Exscientia (NASDAQ:EXAI) Hits New 52-Week Low at $4.13

Shares of Exscientia plc (NASDAQ:EXAI) hit a new 52-week low during trading on Wednesday . The stock traded as low as $4.13 and last traded at $4.16, with a volume of 213422 shares traded. The stock had previously closed at $4.38.

Analyst Ratings Changes

A number of brokerages have issued reports on EXAI. Morgan Stanley reissued an “equal weight” rating and issued a $7.00 target price on shares of Exscientia in a report on Monday. Bank of America lowered shares of Exscientia from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $11.00 to $9.00 in a research report on Friday, January 5th.

Exscientia Stock Up 1.0 %

The business’s 50 day moving average is $5.63 and its 200 day moving average is $5.83. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.22. The stock has a market cap of $487.19 million, a price-to-earnings ratio of -2.72 and a beta of 0.78.

Exscientia (NASDAQ:EXAI) last issued its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. Equities analysts expect that Exscientia plc will post -1.76 earnings per share for the current year.

Institutional Investors Weigh In On Exscientia

Several institutional investors and hedge funds have recently modified their holdings of EXAI. GAMMA Investing LLC lifted its stake in shares of Exscientia by 112.1% in the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after purchasing an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Exscientia by 359.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after acquiring an additional 4,104 shares during the period. Rathbones Group PLC bought a new position in shares of Exscientia during the 3rd quarter worth about $47,000. Tocqueville Asset Management L.P. bought a new position in shares of Exscientia during the 3rd quarter worth about $58,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in shares of Exscientia during the 4th quarter worth about $64,000. Institutional investors and hedge funds own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.